Olga S. Yatskova

Olga S. Yatskova

Auto-generated profile, based on publicly available information

Olga S. Yatskova

Central Polyclinic, Moscow

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2024 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
PDF file
NKNikolay G. Kochergin
Nikolay G. Kochergin
ABAnna A. Brezhneva
Anna A. Brezhneva
OYOlga S. Yazkova
Olga S. Yazkova
AFAlexander A. Fadeev
Alexander A. Fadeev
One of the characteristic features of psoriasis is increased vascularization in the psoriatic plaque. It is known that this process occurs as a result of pathological angiogenesis, which leads to an increase of blood vessels in the lesion, increased proliferation of endothelial cells, vasodilation and increased permeability of the vascular wall, facilitating penetration of immune cells and increasing inflammation. Many signaling molecules are involved in the process of angiogenesis in psoriasis. The most important indicator of the severity of pathological angiogenesis is endothelial vascular growth factor (VEGF). The issue of using blood serum analysis for endothelial vascular growth factor (VEGF) and diagnostic imaging techniques of the vascular network in psoriatic plaques to determine the severity of the process and the possibility of using additional treatment directions aimed at reducing vascularization is being considered. At the moment, the mechanisms of angiogenesis in psoriasis are being actively studied, and the possibilities of therapeutic influence on this link of pathogenesis are especially interesting. The authors present an analysis of the current literature on this topic, and suggest possible available treatment strategies based on the data obtained. Further research in this direction is needed to optimize the therapy of psoriasis, the main purpose of which will be to reduce the duration of treatment and prolong the time of remission.

29 November 2022 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
PDF file
OYOlga S. Yazkova
Olga S. Yazkova
OOOlga Yu. Olisova
Olga Yu. Olisova
EAEkaterina M. Anpilogova
Ekaterina M. Anpilogova
BACKGROUND: Psoriasis is a widespread chronic genetically determined inflammatory dermatosis that affects approximately 125 million people worldwide. In the vast majority of cases, the first rashes appear in people younger than 35 years old who are just starting to build a career and start a family. Localization of psoriatic rashes on visible areas of the skin and stigmatization in society, regular exacerbations and multiple courses of expensive and insufficiently effective treatment negatively affect the quality of life and emotional state of patients up to the development of depressive and anxiety disorders, and even suicide attempts. An imbalance of mental status leads to the progression of psoriasis, which further aggravates the course of the skin process. This necessitates a personalized approach to the choice of a therapy method, taking into account high efficiency and maximum comfort for patients, which will improve their psychoemotional state. AIM: to study the effect of phototherapy (PUVA and UVB-311 nm) on the mental status of psoriasis patients MATERIALS AND METHODS: A prospective study was conducted on the basis of FGKU Central Polyclinic and V.A. Rakhmanovs clinic of skin and venereal diseases of Sechenov University with the participation of 228 patients with moderate-to-severe psoriasis who received UVB-311 nm (n=116) and PUVA therapy (n=112), including psoriasis vulgaris (n=193), guttate psoriasis (n=14), exudative psoriasis (n=21). Before and after treatment, patients were assessed for the severity of psoriasis (PASI), quality of life (DQLI), as well as the presence of depression and anxiety disorders (panic disorder, social phobia) using PHQ-9 and GAD-7 questionnaire tests. The initial radiation dose was 1 J/cm2 at PUVA and 0.10.2 J/cm2 at UVB-311 nm with a gradual increase in the dose every 12 sessions by 0.5 J/cm2 and 0.1 J/cm2, respectively. As photosensitizers ammifurin and oxoralen were used. The treatment was carried out according to the method of four-time irradiation per week using the UV-7001K cabin (Waldmann, Germany). RESULTS: Among 228 patients there were 108 women and 120 men aged 438.2 years. The UVB-311 nm group included 102 patients with moderate psoriasis vulgaris and 14 guttate psoriasis, the second group (PUVA) included patients with severe recalcitrant psoriasis vulgaris (n=91) and exudative psoriasis (n=21). In the first group, the course of therapy consisted of 282 procedures of UVB-311 nm. Before treatment, minimal depression was observed in 19 (16%) patients, mild depression in 87 (75%), moderate depression in 10 (9%). A high level of anxiety was observed in 94 (81%), the average level in 22 (19%) patients. At the end of the course of UVB, PASI 90 was achieved in 94% (n=109) of patients, PASI 100 in 88% (n=102); at the same time, on average, anxiety decreased by 80%, depressive symptoms decreased by 73%, quality of life increased by 92%. In the second group, the PUVA course consisted of 253 irradiation sessions. Before starting therapy, minimal depression was observed in 12 (11%) cases, mild depression in 73 (65%), moderate depression in 27 (24%). A high level of anxiety was characteristic of 100% of patients. As a result of therapy, PASI 90 was achieved in 95.5% (n=107) of cases, PASI 100 in 90% (n=101). The average severity of anxiety, depression, and quality of life improved by 88%, 83%, and 96% respectively. CONCLUSION: PUVA and UVB-311 nm have demonstrated high efficacy and safety in moderate-to -severe psoriasis, contributing to the rapid cleansing of the skin from rashes and improving the psycho-emotional state, which not only significantly improves the quality, but also increases the life expectancy of patients. .

6 February 2025 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
OOOlga Yu. Olisova
Olga Yu. Olisova
OYOlga S. Yazkova
Olga S. Yazkova
EBElizaveta Bystritskaya
Elizaveta Bystritskaya
TRTatiana I. Radchenko
Tatiana I. Radchenko
EZElizaveta I. Zhgelskaya
Elizaveta I. Zhgelskaya
OSOksana Svitich
Oksana Svitich
BACKGROUND: Phototherapy is one of the most effective methods in the treatment of psoriasis, but the mechanism of its action on innate immunity has not been studied. AIM: Investigation of the local expression profile of innate immunity factors in patients with psoriasis during phototherapy. MATERIALS AND METHODS: The study included 31 patients diagnosed with inpatient psoriasis vulgaris. The material for the study was obtained from areas of affected and unaffected skin. Patients with vulgar psoriasis received a course of UVB-311 nm phototherapy lasting from 5 to 7 weeks with a total dose of 35.2 to 44.6 J/cm2. There were 30 healthy people in the control group. Gene expression analysis was performed before treatment and at the end of the phototherapy course. The data obtained were statistically processed. RESULTS: According to the results of the study, gene expression data were obtained: for example, increased expression of the TLR2 and TLR9 genes was observed in the main group after treatment, as well as in samples of unaffected skin from patients. The increased level of the TLR4 gene expression was registered in unaffected skin samples from patients with psoriasis. The expression of the β-defensin 1 gene was elevated in unaffected skin and post-treatment skin. For the cathelicidin gene, there is a difference between the groups of affected and unaffected skin samples before treatment. The expression level of the IL-13 gene was higher before treatment. CONCLUSION: The revealed local imbalance of factors of innate immunity can lead to a more severe course of the disease. The course of phototherapy leads to normalization of the expression profile of receptor and effector molecules of innate immunity, which leads to a stable positive clinical effect.

3 August 2022 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
PDF file
OYOlga S. Yazkova
Olga S. Yazkova
EAEkaterina M. Anpilogova
Ekaterina M. Anpilogova
Psoriasis is a chronic genetically determined disease of a multifactorial nature associated with immune-mediated inflammation and characterized by a recurrent course with frequent associative damage to other organs and systems. According to global recommendations, nowadays, despite the era of biologic therapy, phototherapy (PUVA and UVB) continues to occupy its important niche in the treatment of moderate-to-severe psoriasis, due to the pathogenetically justified therapeutic effect, safety and low cost of procedures. The review provides detailed data on the mechanism of action, the effectiveness of phototherapy; as well as potential biomarkers of psoriasis (calprotectin, lipocalin 2, resistin), which can enhance an accuracy assessment of the effectiveness of the treatment and, if necessary, its timely correction, which will allow faster achievement of the desired effect resulting in improvement of the quality of patients lives.

13 October 2022 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
PDF file
OYOlga S. Yazkova
Olga S. Yazkova
EAEkaterina M. Anpilogova
Ekaterina M. Anpilogova
BACKGROUND:Psoriasis is a widespread, genetically determined immunemediated dermatosis of a multifactorial nature, characterized by a recurrent course with frequent associative damage to other organs and systems, which significantly reduces the quality of patients lives. For many years, phototherapy (PUVA and UVB-311 nm) has had one of the leading places in the treatment of moderate and severe psoriasis according to the world dermatological communities. However, with the advent of genetically engineered biological drugs, the frequency of its administration has significantly decreased. AIM:to evaluate the efficacy and safety of PUVA and UVB-311 nm in the treatment of moderate and severe psoriasis. MATERIALS AND METHODS:A retrospective study was conducted on the basis of the Federal State Institution Central polyclinic with the participation of 920 patients with moderate and severe psoriasis who received phototherapy (PUVA and UVB-311 nm) in the period from 2005 to 2021. The initial radiation dose was 0.51 J/cm2at PUVA and 0.10.2 J/cm2at UVB-311 nm with a gradual increase in the dose every 12 sessions by 0.5 J/cm2and 0.1 J/cm2, respectively. The treatment was carried out according to the method of four-time irradiation per week using the UV-7001K cabin (Waldmann, Germany). RESULTS:Among 920 patients there were 478 (52%) men and 442 (48%) women (aged 21 to 68 years). The average age of psoriasis onset is 345.2 years. The duration of the disease averaged 10.58.2 years. Vulgar psoriasis was observed in 756 (82%) patients, teardrop-shaped ― in 36 (4%), exudative ― in 73 (8%), inverse ― in 55 (6%). 249 (27%) were diagnosed with psoriatic arthritis. On average, the first phototherapy sessions were prescribed 2.11.6 years after the onset of the disease. The choice of phototherapy method depended on the severity of the process. Thus, with moderate psoriasis, patients were prescribed UVB-311 nm (n=473). The course consisted of 2535 sessions of radiation with a cumulative dose of 35.35.9 J/cm2. Clinical remission was observed in 93% of patients, significant improvement ― in 7%. The achieved clinical remission was maintained for 361194 days. In total, during the studied period, 149 people received 27 courses of UVB-therapy, 132 ― 24 courses, 53 ― 19 courses, 69 ― 15 courses, 58 ― 11 courses, 12 ― 7 courses. Multiple infiltrated plaques and refractory course of severe psoriasis was an indication for PUVA therapy (n=447). The course consisted of 2030 irradiation sessions with a cumulative dose of 81.514.3 J/cm2. Clinical remission was observed in 98% of patients, a significant improvement in 2%. 14 people received 23 courses, 21 ― 20 courses, 12 ― 19 courses, 227 ― 15 courses, 104 ― 13 courses, 33 ― 10 courses, 27 ― 4 courses, 9 ― 2 courses of PUVA. The achieved clinical remission was maintained for 420275 days. 12 (1.3%) patients cancelled PUVA prematurely due to the inability to take a photosensitizer. In other cases, the observed side effects were minor and did not cause discontinuation of therapy. CONCLUSION:PUVA and UVB-311 nm have demonstrated high efficacy and safety in the treatment of moderate and severe psoriasis. At the same time, it is necessary to conduct further research to improve the methods of phototherapy for faster achievement of long-lasting clinical remission, which will allow phototherapy to regain its leading position in the treatment of psoriasis, increasing the doctors trust and patients compliance.

12 January 2024 in Russian Journal of Skin and Venereal Diseases
Verified
Journal Article
Open access
PDF file
OYOlga S. Yatskova
Olga S. Yatskova
KTKseniya S. Teplyakova
Kseniya S. Teplyakova
OPOlga A. Pritulo
Olga A. Pritulo
ТСТеплякова Ксения Сергеевна
Теплякова Ксения Сергеевна
BACKGROUND: Currently, psoriasis represents a serious medical and social problem, and it is one of the most common chronic skin diseases. Over the past decades, special attention has been paid to the association of psoriasis with various diseases, such as cardiovascular diseases, inflammatory bowel diseases, depression, etc. Common comorbidities of psoriasis include metabolic syndrome or obesity. Resistin is one of the hormones produced by adipose tissue, the concentration of which increases markedly in patients with psoriasis. Resistin expression is induced by proinflammatory cytokines such as IL-1, IL-6, IL-12 and TNF-a. In turn, an increase in resistin levels leads to increased production of pro-inflammatory cytokines involved in the development of psoriasis, thereby promoting the recruitment of leukocytes during the inflammatory process leading to chronic inflammation. Taken together, the above changes may contribute to the development of metabolic syndrome in psoriasis. Among the effective methods of treating the disease, phototherapy methods (PUVA and UVB 311 nm) remain relevant. Considering these data, it is of interest to study the level of resistin in the serum of patients with psoriasis and its change after a course of PUVA. AIM: The aim of our study was to evaluate the serum resistin level in patients with psoriasis vulgaris before and after PUVA. MATERIALS AND METHODS: The study was conducted at the department of Skin and Venereology diseases at the Sechenov University in the period from June 2022 to November 2023. The study included 30 patients with psoriasis vulgaris of moderate severity (PASI 20), of whom there were 16 men and 14 women. The healthy control group included 20 participants (11 men and 9 women). All patients had blood drawn from a vein during hospitalization and after a course of PUVA. Healthy participants underwent a single blood draw from a vein. RESULTS: A noticeable decrease in the level of resistin in the blood serum was revealed after a course of PUVA in all patients with psoriasis compared to baseline values. In addition, after treatment, resistin levels approached the values recorded in healthy participants. CONCLUSION: Thus, our study allows us to consider resistin as a biological marker of the effectiveness of PUVA in the treatment of patients with psoriasis vulgaris, as well as a predictor of the occurrence of concomitant diseases in patients with psoriasis.